## **EISAI CO. LTD.**

ISIN: JP3160400002 WKN: 4523 Asset Class: Stock



## **Company Profile**

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

## Financial figures, Fiscal year: from 01.04. to 31.03. 2022 2021 2023 **Financial figures** Assets Liabilities and equity Assets Liabilities and equity Assets Liabilities and equity **Current assets** 621,847,000,000 640.260.000.000 517,886,000,000 Common stock capital 44,986,000,000 44,986,000,000 44,986,000,000 **Fixed assets** 641,503,000,000 599,055,000,000 572,123,000,000 Equity capital of a company 822,571,000,000 771,533,000,000 727,942,000,000 267,350,000,000 309,633,000,000 248,740,000,000 Cash and cash equivalents **Accrued liabilities** 1.299.000.000 1.473.000.000 10.164.000.000 Other assets **Current liabilities** 298.945.000.000 313.333.000.000 256,017,000,000 Prepayments and accrued income Non-current liabilities 141,834,000,000 154,448,000,000 106,050,000,000 Different income

Other liabilities		19,096,000,000		19,407,000,000		4,092,000,000
Total assets	1,263,350,000,000	1,263,350,000,000	1,239,315,000,000	1,239,315,000,000	1,090,009,000,000	1,090,009,000,000
Balance notes						
				2023	2022	2021
Accounting standard				IFRS	IFRS	IFRS
Employees				11,076	11,322	11,237
Equity ratio				66.90%	64.09%	69.05%
Debt-equity ratio				49.48%	56.04%	44.81%
Others						
				2023	2022	2021
Tax Expense Rate				-26.27%	16.05%	19.16%

## **EISAI CO. LTD.**

ISIN: JP3160400002 WKN: 4523 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	744,402,000,000	756,226,000,000	645,942,000,000
Net income	55,432,000,000	47,954,000,000	42,119,000,000
EBIT	255,930,000	326,802,000	314,658,000
Operating income before taxes	45,012,000,000	54,458,000,000	52,551,000,000
Cash Flow	-1,772,000,000	117,590,000,000	73,853,000,000
Net interest income	2,357,000,000	-9,000,000	108,000,000
Research and development expenses	156,691,000,000	158,030,000,000	138,822,000,000
Income taxes	-11,824,000,000	8,741,000,000	10,068,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	403,251	400,756	344,901

Member of Supervisory Board
Member of Supervisory Board

Members of Management Board		
Haruo Naito	Chairman of Managing Board	
Akiko Nakahama	Member of Executive Committee	
Gary Hendler	Member of Executive Committee	
Ivan Cheung	Member of Executive Committee	
Kazuhiko Tamura	Member of Executive Committee	
Keisuke Naito	Member of Executive Committee	
Kenta Takahashi	Member of Executive Committee	
Lynn Kramer	Member of Executive Committee	
Masatomi Akana	Member of Executive Committee	
Mitsuo Kosaka	Member of Executive Committee	
Mitsuru Shomon	Member of Executive Committee	
Sayoko Sasaki	Member of Executive Committee	
Shin Ujiie	Member of Executive Committee	
Shohei Kanazawa	Member of Executive Committee	
Takashi Owa	Member of Executive Committee	
Tatsuyuki Yasuno	Member of Executive Committee	
Terushige like	Member of Executive Committee	
Teruyuki Masaka	Member of Executive Committee	
Toshitaka Asano	Member of Executive Committee	
Yanhui Feng	Member of Executive Committee	
Yasushi Okada	Member of Executive Committee	